Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Operating expense | 38M | 5.5% |
| Net Income | -36M | 4.4% |
| EBITDA | -38M | 7% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 220M | 13.4% |
| Total Liabilities | 18M | 36.8% |
| Total Equity | 201M | 22.2% |
| Shares Outstanding | 86M | 24.9% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -40M | 32.5% |
| Cash from financing | 66M | 59592.7% |
EPS
Financial Highlights for Amylyx Pharmaceuticals in Q1 '25
Operating Expenses for this period were 38M, showing a -5.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -36M, showing a 4.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -38M, showing a 7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Amylyx Pharmaceuticals with growth in revenue, gross profit, and net income.
